Edwards Lifesciences (EW) stock faces a downgrade at Wolfe due to concerns over its TAVR market prospects. Read more here.

The following is a summary of “Computed tomography derived predictors of left ventricular obstruction after TAVR,” published ...

Risk for bleeding events is significantly affected by DOAC score in patients with atrial fibrillation who have received TAVR.

An innovative heart procedure is changing the lives of patients with aortic valve disease. It's called transcatheter aortic valve replacement — or TAVR. We're learning more with BayCare.

Wedgewood Partners, an investment management company, released its fourth-quarter 2024 investor letter. A copy of the letter ...

The transcatheter aortic valve implantation gives patients the opportunity to continue their daily lives with minimal ...

The global cardiovascular devices market, valued at US$ 72.83 billion in 2023, is forecasted to grow at a robust CAGR of 7.3% ...

General Hospital, Ernakulam, nears first heart transplant surgery with successful TAVR procedures and upcoming patient screenings.

Wolfe Research downgraded Edwards Lifesciences (EW) to Underperform from Peer Perform with a $60 price target The firm says its core ...

Doylestown Health’s Heart and Vascular Services team recently performed its 1,000th transcatheter aortic valve replacement at ...